Search results
Results from the WOW.Com Content Network
Merck's Keytruda generates over $20 billion in sales annually, an incredibly rare feat for a medicine. ... if you invested $1,000 at the time of our recommendation, ... and two new stock picks ...
Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody, more specifically a PD-1 inhibitor, used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer.
Within the year of 2014, the cost of prescriptions had increased by at least 11.4% and 58% within the last eight years. The average cost for a month supply of brand-name drugs can run up to a couple of hundred US dollars, whereas in Canada and Great Britain the same medication could cost up to $40 US dollars.
Keytruda, approved for several types of cancer, alone accounts for more than 25% of Merck's (MRK) pharmaceutical sales Animal health and vaccine products remain core growth drivers.
Merck's top-selling drug Keytruda helps the body's own immune system fend off cancer by blocking a protein called PD-1. It has been approved to treat more than ten kinds of cancer.
Side effects from hormonal contraceptives typically disappear over time (3-5 months) with consistent use. [16] Less common effects of combined hormonal contraceptives include increasing the risk of deep vein thrombosis to 2-10 per 10,000 women per year and venous thrombotic events (see venous thrombosis) to 7-10 per 10,000 women per year. [15]
Merck's (MRK) Keytruda is rapidly gaining strength as a key contributor to the company's top line. The Keytruda development program is also progressing well. Merck's Keytruda Picks Up Pace in ...
For premium support please call: 800-290-4726 more ways to reach us